MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY

被引：1
|
作者：
Jiang, Y. [1 ]
Gauthier, A. [1 ]
Annemans, L. [2 ]
van der Linden, M. [3 ]
Nicolas-Spony, L.
Bresse, X. [4 ]
机构：
[1] Amaris Consulting UK, London, England
[2] Univ Ghent, B-9000 Ghent, Belgium
[3] Natl Reference Ctr Streptococci, Aachen, Germany
[4] Sanofi Pasteur MSD, Lyon, France
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.205
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A268 / A268
页数：1
相关论文
共 50 条
  • [1] A BUDGET IMPACT (BI) ANALYSIS OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UK
    Jiang, Y.
    Gauthier, A.
    Keeping, S. T.
    Carroll, S. M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A388 - A388
  • [2] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION, THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13), OR PCV13 FOLLOWED BY PPV23 IN BRAZIL
    Jiang, Y.
    Yang, X.
    Petigara, T.
    Chabrol Haas, L.
    Graham, J.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A930 - A930
  • [3] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
    Prieto, E.
    Jiang, Y.
    Yang, X.
    Graham, J. B.
    Monsanto, H.
    Ruiz, J.
    Beltran, C.
    Rojas, M.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
  • [4] ASSESSING THE COST-EFFECTIVENESS (CE) OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC) IN THE UK
    Jiang, Y.
    Gauthier, A.
    Keeping, S. T.
    Carroll, S. M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A396 - A397
  • [5] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
    Wu, D. B. C.
    Chang, C. J.
    Chien, L.
    Fang, H. C. H.
    Roberts, C. S.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
  • [6] A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 901 - 911
  • [7] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [8] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
    Shiramoto, Masanari
    Hanada, Ryuzo
    Juergens, Christine
    Shoji, Yasuko
    Yoshida, Mizuki
    Ballan, Barry
    Cooper, David
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
  • [9] Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
    Garcia Garrido, Hannah M.
    Vollaard, Albert
    D'Haens, Geert R.
    Spuls, Phyllis I.
    Bemelman, Frederike J.
    Tanck, Michael W.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    [J]. VACCINES, 2022, 10 (05)
  • [10] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
12345